FdaApplication
NDA 220018
Identifiers
- fda_app_no: NDA220018
Properties
| Property | Value |
|---|---|
| applicant_name | GILEAD SCIENCES INC |
| application_type | NDA |
| approval_date | 2025-06-18 |
Revenue by product
YEZTUGO
| Period | Revenue |
|---|---|
| Q2 2026 | $232.0M |
| Q1 2026 | $166.0M |
| Q2 2025 | $15.0M |
| Q1 2025 | $0.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients.
Products (2)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| YEZTUGO | LENACAPAVIR | 463.5MG/1.5ML(309MG/ML) | SOLUTION;SUBCUTANEOUS |
| YEZTUGO | LENACAPAVIR SODIUM | EQ 463.5MG BASE/1.5ML (EQ 309MG BASE/ML) | SOLUTION;SUBCUTANEOUS |
2 products